<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565109</url>
  </required_header>
  <id_info>
    <org_study_id>NESC</org_study_id>
    <nct_id>NCT01565109</nct_id>
  </id_info>
  <brief_title>NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma</brief_title>
  <official_title>Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Sainte Catherine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Sainte Catherine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is estimated to 7300 the number of new cases of gastric cancer each year in France.&#xD;
&#xD;
      According to a randomized trial comparing 3 cycles of ECF (epirubicin, cisplatin, 5FU)&#xD;
      administered before surgery and 3 cycles after surgery with surgery alone in adenocarcinoma&#xD;
      of the stomach and lower esophagus, clinical and experimental data are the neoadjuvant&#xD;
      chemotherapy is a new standard treatment for operable gastric cancer. This treatment with a&#xD;
      median survival of more than 3 years to obtain a hazard ratio of 0.75 in favor of&#xD;
      chemotherapy arm (p = 0.009). The 5-year survival being 36% for patients treated with&#xD;
      chemotherapy versus 23% for surgery alone. Progression-free survival was also significantly&#xD;
      prolonged with a hazard ratio of 0.66.&#xD;
&#xD;
      The proposed clinical study by Ajani et al shows that the combination of Docetaxel with the&#xD;
      schema Cisplatin - 5FU provides greater clinical benefit and induces to consider the triple&#xD;
      combination as a reference treatment in metastatic gastric cancer in patients under 65 years.&#xD;
&#xD;
      Preoperative radiochemotherapy is expected to increase the rate of curative resections,&#xD;
      reduce gastrointestinal and hematologic toxicity.&#xD;
&#xD;
      Two studies evaluating the feasibility of preoperative RTCT in operable gastric&#xD;
      adenocarcinoma with continuous 5GU (+ or - paclitaxel) and 45 Gy are available and the&#xD;
      combination 5FU oxaliplatin has been assessed in the esophagus and rectum tumors.&#xD;
&#xD;
      The NESC study, Phase II, proposes the following schema: 2 cycles of chemotherapy with&#xD;
      Docetaxel - Cisplatin - 5FU then preoperative chemoradiation with oxaliplatin - continuous&#xD;
      5FU and radiotherapy in locally advanced gastric adenocarcinoma stage III and IV&#xD;
      non-metastatic administered before surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological response rate on surgical specimen after chemotherapy and chemoradiotherapy preoperative</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU&#xD;
Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel - Cisplatine - 5FU</intervention_name>
    <description>2 cycles of Docetaxel - Cisplatine - 5 FU</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation of 45 Grays on 5 weeks</intervention_name>
    <description>Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, Age: 18 to 65&#xD;
&#xD;
          -  ECOG performance status of ≤ 1&#xD;
&#xD;
          -  Histological documentation of the gastric adenocarcinoma. An extension will be&#xD;
             admitted to the omentum&#xD;
&#xD;
          -  Adenocarcinoma of the stomach according to staging classification TNM Scannographic:&#xD;
             T2bN0, T2bN1, T3NO T3N +, T4N0, and T4N + M0 (cardia, Siewert II, III, fundus, body,&#xD;
             antrum) performed by ultrasonography and CT Scan. Optional : laparoscopy&#xD;
&#xD;
          -  A positive peritoneal cytology is not a disqualifying factor if there is no&#xD;
             macroscopic carcinomatosis&#xD;
&#xD;
          -  Absence of previous abdominal irradiation above the 5th sacral vertebra (in the liver,&#xD;
             pancreas, spleen, or mediastinal lodge)&#xD;
&#xD;
          -  Loss of weight less than 15% over the base weight before diagnosis&#xD;
&#xD;
          -  No psychological, familial, sociological or geographical condition that may affect&#xD;
             compliance and adherence to treatment, patient monitoring or understanding of the&#xD;
             study.&#xD;
&#xD;
          -  Signed informed consent obtained before any study specific procedures.&#xD;
&#xD;
          -  Food Consumption&gt; 1000 calories / day whatever the mode of administration (enteral or&#xD;
             parenteral)&#xD;
&#xD;
          -  Laboratory test conducted within one week of starting to study treatment:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/mm3&#xD;
&#xD;
               -  Platelet count &gt; 100 000/mm3&#xD;
&#xD;
               -  Total bilirubin &lt;2 mg/dL&#xD;
&#xD;
               -  Serum creatinine &lt;13 mg/dL or creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 10 g/dL (Hemoglobin transfusion if necessary)&#xD;
&#xD;
               -  ALT / AST &lt;1.5 x ULN&#xD;
&#xD;
               -  PTT ≥ 60 %&#xD;
&#xD;
               -  Life expectancy of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral sensory neuropathy ≥ grade 1 (according to CTCAE version 3.0).&#xD;
&#xD;
          -  Myocardial infarction, stroke or pulmonary embolism, unstable angina less than 6&#xD;
             months before start of study drug.&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             pregnancy test performed.&#xD;
&#xD;
          -  Prior treatment for gastric adenocarcinoma&#xD;
&#xD;
          -  Lower limbs arteritis (≥ stage II according the Leriche and Fontain classification)&#xD;
&#xD;
          -  Patient participating in another clinical trial or already receiving other anti-cancer&#xD;
             treatment&#xD;
&#xD;
          -  Concomitant treatment with a phenytoin&#xD;
&#xD;
          -  Known previous / current malignancy within the last 5 years except for non-melanoma&#xD;
             skin, non-metastatic prostate carcinoma and cervival carcinoma in situ or superficial&#xD;
             bladder carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURENT MINEUR, DOCTOR</last_name>
      <phone>04.90.27.62.68</phone>
      <email>l.mineur@isc84.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Sainte Catherine</investigator_affiliation>
    <investigator_full_name>Dr.Laurent Mineur</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>NESC</keyword>
  <keyword>NEOADJUVANT</keyword>
  <keyword>GASTRIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

